No Data
Zhi Jiang Bio (688317.SH): Cumulative repurchase of 1.14% of company shares.
On August 1st, Gelonhui announced that as of July 31, 2024, the company has repurchased 2,199,975 shares through the Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 1.14% of the company's current total share capital of 192,157,999 shares. The highest transaction price for the repurchase is 17.29 yuan/share, the lowest is 13.79 yuan/share, and the total amount paid is RMB 33,553,460.28 (excluding stamp duty, transaction commission and other transaction costs).
Zhi Jiang Biology (688317.SH): Recently, 5 products have obtained relevant certifications, further enhancing the company's international competitiveness.
On July 21st, Gelunhui reported that Zhejiang Biomedical Technology Co., Ltd. and its wholly-owned subsidiary, Shanghai Zhejiang Biomedical Technology Co., Ltd. obtained certification for five of their products. After obtaining certification, these products can be sold in Turkey and other countries recognized by Turkey's certification system, enhancing the company's international competitiveness and playing a positive role in expanding the company's overseas sales and international business categories.
Zhi Jiang Bio (688317.SH): cumulative repurchase of 1.01% of the company's shares.
On July 10th, GeLongHui announced that Zhejiang Hisun Pharmaceutical (stock code: 688317) had repurchased 1.945 million shares of the company through the Shanghai Stock Exchange trading system by centralized bidding trading method until July 9th, 2024, accounting for 1.01% of the total share capital of the company, which is 192,157,999 shares currently. Compared with the last disclosed data, the proportion has increased by 0.04%. The highest purchase price of the repurchase transaction was 17.29 yuan per share, and the lowest price was 13.79 yuan per share. The total amount paid, excluding transaction fees such as stamp duty and commission, was RMB 29.9484 million yuan.
Zhejiang Hisun Pharmaceutical (688317.SH): Cumulative expenditure of 28.76 million yuan to repurchase 0.97% of shares.
On July 2nd, Gelonhui reported that as of June 30th, 2024, the company had repurchased 1,859,987 shares of its own stock through the Shanghai Stock Exchange's trading system using centralized auction trading, accounting for 0.97% of the total current shares of 192,157,999 shares of the company, with a highest repurchase price of 17.29 yuan/share, a lowest price of 13.79 yuan/share, and a total payment of RMB 28,764,674.45 (excluding transaction fees such as stamp duty and commission).
Zhi Jiang Biological (688317.SH): Cumulative spending of 22.73 million yuan to repurchase 0.74% of shares.
On June 4th, Gelon Hui reported that Zhejiang Hisun Pharmaceutical Co., Ltd. (688317.SH) had accumulated repurchased 1,442,987 shares of the company through the Shanghai Stock Exchange trading system by centralized bidding trading as of May 31, 2024. The proportion of repurchased shares accounted for 0.74% of the company's total share capital of 194,704,350 shares. The highest and lowest transaction prices for the repurchase were 17.29 yuan/share and 13.79 yuan/share, respectively, with a total payment of RMB 22,732,140.99 yuan (exclusive of stamp duty, transaction fees, and other expenses).
Zhijiang Biotech (688317.SH): 3 products obtained relevant certification from the Food and Drug Administration of Thailand
Zhitong Finance App News, Zhijiang Biotech (688317.SH) announced that the company recently obtained relevant certification from the Food and Drug Administration of Thailand. The product names are High-Risk Human Papillomavirus (HPV) and Genotyping 16&18 Diagnostic Kit (PCR-fluorescence) high-risk human papillomavirus (HPV) nucleic acid testing and 16/18 typing kit (fluorescence PCR method), High-risk Hum
Some Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) Shareholders Look For Exit As Shares Take 27% PoundingNo Data
